Skip to main content

Type 1 Diabetes News

Type 1 Diabetes is a chronic condition in which your body loses the ability to produce insulin, which is necessary for most cells to convert food into energy and regulate blood sugar levels. 

Training to be tested in a small group before the full launch starts in June
A new basal insulin is on the horizon in the US with Merck’s LUSDUNA Nexvue, but launch timing obscured by ongoing lawsuit
Initiative encourages pump and CGM devices to use “open protocols” to enable the DIY community, innovation, and more options for automated insulin delivery
Last chance to register for this amazing event!
Best-selling author on why he believes “calories in-out” is not an explanation for obesity, why we need better science, and nutrition recommendations for people with...
Includes insulin dose advisor software; plus, a new Novo Nordisk connected Echo insulin pen to debut in Europe later this year
What’s new in smart pens and caps for capturing injection doses? Plus, two cool new health apps with built-in artificial intelligence
Jim Hirsch, diaTribe contributor and bestselling author, weighs in on a damaging diabetes myth
The lame food advice at Adam Brown's diagnosis, why it didn’t work, and Adam's #1 Bright Spot solution
What it’s about, how to get a free copy, and three myths I want to bust
iPhone users will be able to share insulin dose data between apps, paving way for ecosystem with smart pens and connected pumps
Research presented at EASD 2017 showcased drugs, both new and old, that improve blood sugar management, weight loss, heart health, and even blood pressure
Get your copy at diaTribe.org/BrightSpots for free or name-your-own-price
How to overcome the most frustrating diabetes landmine
Major win to complement Lilly’s partnership with Dr. Ed Damiano and the Bionic Pancreas team; insulin-only pivotal trial in late 2017/early 2018
Kerri Sparling on what it’s like to (attempt) balance raising young kids with managing diabetes – and how kids can be the best diabetes motivators
The diaTribe Foundation and TCOYD host discussion at ADA focusing on access, outcomes beyond A1c, and future expectations
Faster version of Novo Nordisk’s NovoLog approved in the US for type 1 and type 2 diabetes, launch expected as early as end of 2017
People with type 1 or type 2 diabetes on intensive insulin therapy can qualify. A major win for the diabetes community following years of patient advocacy!
The 2017 Patient Voices Contest is currently open; winners will receive a full scholarship to attend the 2017 DiabetesMine Innovation Summit in Palo Alto

Pages